Clinical Trial

The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF burden. Secondary objectives of the study are the following: * To investigate the impact of catheter ablation on serum pro-thrombotic biomarkers in patients with AF. * To correlate coagulation biomarkers with imaging features such as, the degree of fibrosis found on Late Gadolinium Enhancement Magnetic Resonance Imaging (LGE-MRI) scans, which is a part of standard of care. * To determine baseline values of coagulation and pro-thrombotic biomarkers in the AF population and compare those baseline values with the general population values. * To compare central and peripheral thrombotic biomarkers in patients with atrial fibrillation.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-06-30; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2021-09-29
Trial Details
NCT Number NCT04947657
Lead Sponsor Tulane University
Conditions Atrial Fibrillation
Enrollment 20 participants
Start Date 2021-09-22
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-05